RPG Life Sciences Ltd
RPG Life Sciences Ltd (RPGLIFE) last traded at ₹2,585, a market capitalisation of ₹4,275 crore, on a P/E of 36.6. Over the past 52 weeks the stock has ranged between ₹1,731 and ₹3,082. RPG Life Sciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹196 crore and net profit of ₹31 crore. The next scheduled event is an analyst meet on 2 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
RPG Life Sciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
RPG Life Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹196 cr, up 16.0% from ₹169 cr a year earlier. Net profit was ₹31 cr, up 19.2% year on year.
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 173 | 143 | 169 | 182 | 180 | 177 | 196 |
| Expenses | 124 | 118 | 133 | 143 | 140 | 144 | 152 |
| Operating profit | 49 | 25 | 35 | 39 | 40 | 33 | 43 |
| OPM % | 28% | 18% | 21% | 21% | 22% | 19% | 22% |
| Other income | 3 | 115 | 5 | 16 | -5 | 14 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 47 | 135 | 35 | 49 | 29 | 40 | 41 |
| Tax % | 26% | 13% | 26% | 25% | 24% | 26% | 26% |
| Net profit | 35 | 117 | 26 | 37 | 22 | 30 | 31 |
| EPS (₹) | 21.12 | 70.95 | 15.90 | 22.28 | 13.38 | 18.08 | 18.60 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
RPG Life Sciences Ltd annual results
| ₹ crore | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 653 | 708 | 734 |
| Operating profit | 161 | 148 | 155 |
| OPM % | 25% | 21% | 21% |
| Net profit | 183 | 115 | 120 |
| EPS (₹) | 110.79 | 69.64 | 72.34 |
TTM is the trailing twelve months to the most recent quarter.
RPG Life Sciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 8%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -5%
- 10 Years
- 20%
- 5 Years
- 40%
- 3 Years
- 30%
- 1 Year
- 12%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 19%
RPG Life Sciences Ltd shareholding pattern
Promoters held 72.95% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.95% and DIIs 8.68%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.82% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| FIIs | 1.35% | 1.30% | 1.46% | 1.35% | 1.11% | 1.00% | 0.87% | 0.95% |
| DIIs | 5.45% | 6.06% | 6.14% | 6.49% | 6.70% | 7.04% | 7.45% | 8.68% |
| Public | 20.40% | 19.70% | 19.46% | 19.22% | 19.23% | 19.01% | 18.72% | 17.42% |
| No. of shareholders | 23,481 | 24,891 | 24,867 | 25,832 | 26,657 | 25,905 | 25,282 | 23,886 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming RPG Life Sciences Ltd events
The next scheduled event is an analyst meet on 2 Sept 2026.
- Analyst meetParticipation in Ashwamedh – Elara India Dialogue 2026
See the full results calendar for every Indian company reporting in the next 30 days.
RPG Life Sciences Ltd corporate filings
- The Company has informed about the Schedule of Analyst/Institutional Investors MeetCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has announced a scheduled meeting with analysts and institutional…
Read the full analysis - The Company has informed about the Schedule of Analyst/Institutional Investors MeetCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has announced a scheduled meeting with analysts and institutional…
Read the full analysis - Resignation of Senior Management PersonnelCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences Limited has announced that Mr. Deepak Shukla has resigned as Chief…
Read the full analysis - Completion of transactions in API Business Transfer Agreement with RPG Active Pharma Limited.Company Updatelow impact
Cruxal's analysis: RPG Life Sciences has officially completed the transaction regarding the transfer of its…
Read the full analysis - RPG Life Sciences Limited has informed the Exchange about the Further investment in RPG Active Pharma LimitedCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences Limited has disclosed a further investment in its subsidiary, RPG…
Read the full analysis - Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the details of the Analyst/Institutional ....Company Updatelow impact
Cruxal's analysis: RPG Life Sciences has issued an intimation regarding an upcoming Analyst/Institutional…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track RPG Life Sciences Ltd
Cruxal reads every RPG Life Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.